Anti-troll bill may expand CBM review to all patents

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Anti-troll bill may expand CBM review to all patents

A new bill aiming to curb patent trolls by expanding post-grant patent challenge proceedings has been introduced in the United States

The Stopping the Offensive Use of Patents (STOP) Act, which was introduced by Representatives Darrell Issa and Judy Chu, would expand Covered Business Method (CBM) Review under the AIA to include all types of patents.

The CBM review trial was introduced under the AIA to reduce the number of overly broad business method patents. A party accused of infringing a patent that is covered under Section 18 of the AIA can use the CMB review system to challenge its validity through the USPTO’s Patent Trial and Review Board (PTAB) as an alternative to litigation.

CBM review was introduced as a temporary measure in September 2012. It will end on September 15 2020, after which the USPTO will not accept any new petitions for CBM review.

The STOP Act, however, would make the PTAB proceedings permanent. It was drafted in conjunction with Senator Chuck Schumer, who has been working on the Patent Quality Improvement Act, and incorporates parts of that bill with some adjustments to tailor it to the AIA.

Laurent Crenshaw, Issa’s legislative director, told reporters during a press conference today that it is much cheaper for businesses to challenge the validity of patents under post-grant proceedings than it is for them to pursue litigation. The cost of attempting to have a patent invalidated under the STOP Act would be around $100,000 in fees and costs, including around $30,000 in USPTO fees, compared to multimillion-dollar litigation. In addition, multiple businesses targeted by one troll can split the fees and costs for the proceeding.

Crenshaw acknowledged that the bill is only a partial solution to the patent troll problem. Other pending legislation attempts to address other aspects of the issue, such as the litigation strategies employed by trolls.

“We are quite aware that there are other Congressional offices that are looking at other aspects of the problem so we don’t see this as being the end-all solution but we see it as a very important part of a problem that needs to be dealt with,” said Crenshaw.

The bill is supported by the Food Marketing Institute, an industry association that represents supermarkets. Retailers have increasingly become targets of patent trolls.

“The average profit in our industry is less than 1% so consumers absolutely take a hit from trolls,” said Erik Lieberman, regulatory counsel for the Food Marketing Institute. “Food prices are already forecast to increase by 3-5% this year.”

He said the Institute’s members often face demands from patent assertion entities for commonly used features such as rendering JPEGs and sending out text messages that have links embedded in them.

He described the STOP Act as “very important legislation that will help address the problem of trolls”.

more from across site and SHARED ros bottom lb

More from across our site

The Texas-based IP litigation hires take King & Spalding’s partner appointments from pre-merger Winston & Strawn up to 12 this year
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Simon Wright explains why the UK should embrace the possibility of rejoining the UPC, and reveals how CIPA is reacting to this month’s historic Emotional Perception AI case at the UK Supreme Court
Gift this article